Defects in apoptosis are common in CRC and are mainly due to inactivating mutations in TP53, and increased expression of anti-apoptotic proteins (e.g., BCL-2, BCL-XL) or decreased expression of pro-apoptotic proteins (e.g., BAX, BIM) [47]. This evidence concerns the gene BCL2 and colorectal carcinoma.